InvestorLens

AKTS — AKTIS ONCOLOGY INC

Public company

Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying AKTS?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
50
Institutional Conviction
Net distribution · 1 buying vs 1 selling last quarter
37
Macro Tailwind
Macro conditions are mixed for this sector
55
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their AKTS position last quarter, 1 bought and 1 sold (50% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime).

Supporting evidence
  • +1 tracked investor added or increased positions last quarter (Paul Tudor Jones)
  • +3 tracked investors reported holding AKTS at their latest filing
  • +Macro Health is 55/100 in a Squeeze regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.

About AKTIS ONCOLOGY INC (AKTS)

AKTIS ONCOLOGY INC (AKTS) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by George Soros (Soros Fund Management), valued at $3M. Across recent filings, tracked investors recorded 2 new positions, 0 increased, 1 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in AKTS

67
/100
Institutional Accumulation
Added / Increased2
Reduced1
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track AKTS

20
/100
Emerging Interest
3investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

AKTS Ownership Composition

How AKTIS ONCOLOGY INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Macro
83% of tracked value
Institutions
3
tracked investors
Total Reported
$4.7M
combined 13F value
Types2
  • Macro82.6%
  • Multi-Strategy / Quant17.4%
Macro(2)
82.6%
Multi-Strategy / Quant(1)
17.4%

Tracked investors currently reporting AKTS

  • George SorosJun 30, 2026
    Soros Fund Management
    Shares
    100K
    Value
    $3.2M
    % Portfolio
    0.04%
  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    25.5K
    Value
    $823.1K
    % Portfolio
    0.00%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    21.4K
    Value
    $689.8K
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold AKTS?
3 tracked institutional investors disclosed a position in AKTS (AKTIS ONCOLOGY INC) in their most recent 13F filing.
Who is the largest institutional holder of AKTS?
George Soros, Soros Fund Management, holds the largest disclosed position in AKTS, valued at $3M.
Did institutional ownership of AKTS increase or decrease?
Across recent 13F filings, tracked investors recorded 2 new positions, 0 increased, 1 reduced, and 0 fully exited AKTS.
Where does this AKTS ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.